HTB

14 March 2018: vol 19 no 5

This edition of HTB includes the first reports from CROI 2018, with additional reports following in subsequent issues. 

Important themes this year included cure-related research, TB coinfection, PrEP and new antiretroviral drugs.

As usual, webcasts and conference material are already online.

Also, news that after more than a decade in development, the monoclonal antibody ibalizumab has been approved in the US as a treatment for multidrug resistant HIV.

This drug will be a life-saving option for some people, although it is still dependent on being used in combination with other active HIV drugs.

As we went to press it was still unclear whether there are plans to apply for approval in the EU.

Links to other websites are current at date of posting but not maintained.